To improve a promising cancer drug, cut it in half

by Ian Haydon,University of Washington School of MedicineNeoleukin-2/15 can be split into two fragments that reconstitute its activity when combined. a, Splitting strategy for Neo-2/15. Structur

Updated on: January 08,2024

To improve a promising cancer drug, cut it in half

by Ian Haydon,University of Washington School of MedicineNeoleukin-2/15 can be split into two fragments that reconstitute its activity when combined. a, Splitting strategy for Neo-2/15. Structur

Updated on:January 08,2024

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on: October 30,2023

Study identifies skin microbiome as a factor in stem cell transplants

Study identifies skin microbiome as a factor in stem cell transplantsbyMedical University of ViennaCredit: AI-generated imageOrgan damage occurs in up to 70% of patients in the first few months

Updated on:October 30,2023

Mayo Clinic Minute: Learning the 'ABCDEs' of melanoma

by Alex OsiadaczMelanoma. Credit: Wikimedia Commons/National Cancer InstituteMelanoma is a type of skin cancer that develops in cells that produce your skin's pigment. Regular skin checks can help

Updated on: December 18,2023

Mayo Clinic Minute: Learning the 'ABCDEs' of melanoma

by Alex OsiadaczMelanoma. Credit: Wikimedia Commons/National Cancer InstituteMelanoma is a type of skin cancer that develops in cells that produce your skin's pigment. Regular skin checks can help

Updated on:December 18,2023

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results i

Updated on: October 23,2023

Dual-action drug produces positive results in patients with advanced neuroendocrine tumors

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainA drug that simultaneously strikes cancer cells' growth circuits and pipeline to the bloodstream produced encouraging results i

Updated on:October 23,2023

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on: October 17,2023

3-Week Course of Radiotherapy May Offer Greater Convenience for Patients With Soft Tissue Sarcoma

December 29, 2022Jason HarrisModerately hypofractionated preoperative radiotherapy did not increase risk for major wound complication in patients with soft tissue sarcomas, according to findings from

Updated on:October 17,2023

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on: October 17,2023

Frontline Eganelisib Triplet Provides Potential Long-term PFS Benefit in Metastatic TNBC

November 15, 2022Kristi RosaThe addition of eganelisib to atezolizumab and nab-paclitaxel demonstrated evidence of a long-term progression-free survival benefit when used as first-line treatment in pa

Updated on:October 17,2023

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on: December 21,2023

Novel subtype of nasopharyngeal carcinoma and Epstein-Barr virus–associated immune suppression discovered

Updated on:December 21,2023

Treatment without hormone blockers improves outcomes in solitary prostate cancer metastases

byWolters Kluwer HealthA, Prostate specific antigen (PSA) waterfall plot for surgical metastasis-directed therapy. B, PSA waterfall plot for stereotactic body radiation therapy metastasis-direct

Updated on: December 19,2023

Treatment without hormone blockers improves outcomes in solitary prostate cancer metastases

byWolters Kluwer HealthA, Prostate specific antigen (PSA) waterfall plot for surgical metastasis-directed therapy. B, PSA waterfall plot for stereotactic body radiation therapy metastasis-direct

Updated on:December 19,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on: October 15,2023

ICI-Treated Synchronous mRCC Is Associated With Negative Survival Outcomes

July 17, 2023Ashling WahnerPatients with synchronous metastatic renal cell carcinoma who received first-line immunotherapy had worse survival outcomes compared with those with metachronous metastatic

Updated on:October 15,2023

Automated detection of eye surface cancer

by ARC Centre of Excellence for Nanoscale BioPhotonicsA new automated non-invasive technique for diagnosing eye disease. Credit: ARC Centre of Excellence for Nanoscale BioPhotonicsResearchers hav

Updated on: May 25,2024

Automated detection of eye surface cancer

by ARC Centre of Excellence for Nanoscale BioPhotonicsA new automated non-invasive technique for diagnosing eye disease. Credit: ARC Centre of Excellence for Nanoscale BioPhotonicsResearchers hav

Updated on:May 25,2024

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on: December 17,2023

PSMA PET scanning can improve decision making for prostate cancer treatment

bySociety of Nuclear MedicineHeat map of prostate bed PSMA PET recurrences distribution in the miTr N0 Mo cohort (n=127 patients) mapped on a template patient’s anatomy (the green contour repres

Updated on:December 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on: October 17,2023

Cilta-cel Provides Durable Responses in Lenalidomide-Refractory Myeloma After 1 to 3 Prior Lines

August 28, 2022Kristi RosaCiltacabtagene autoleucel elicited encouraging responses in patients with multiple myeloma who had received 1 to 3 prior lines of therapy and were refractory to lenalidomide.

Updated on:October 17,2023